The endogenous anti-angiogenic family of splice variants of VEGF, VEGF xxxb, are down-regulated in pre-eclamptic placentae at term

Clinical Science

Volumn 110, Issue 5, 2006, Pages 575-585

  Bates, David O ^a   MacMillan, Philip P ^a   Manjaly, Joseph G ^a   Qiu, Yan ^a   Hudson, Sarah J ^a   Bevan, Heather S ^a   Hunter, Alyson J ^a   Soothill, Peter W ^a   Read, Michael ^b   Donaldson, Lucy F ^a   Harper, Steven J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

Pre eclampsia; Splice variant; Vascular endothelial growth factor (VEGF); Vascular permeability

Indexed keywords

GROWTH FACTOR; ISOPROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULAR EPITHERLIAL GROWTH FACTOR 121B; VASCULAR EPITHERLIAL GROWTH FACTOR 145B; VASCULAR EPITHERLIAL GROWTH FACTOR 165B; VASCULOTROPIN; VASCULOTROPIN 165; VASCULOTROPIN 189; VASCULOTROPIN 206; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; RNA SPLICING; UPREGULATION; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; DOWN-REGULATION; FEMALE; HUMANS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33646711885     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050292     Document Type: Article

References (49)

1. Roberts, J. M., Taylor, R. N., Musci, T. J., Rodgers, G. M., Hubel, C. A. and McLaughlin, M. K. (1989) Preeclampsia: an endothelial cell disorder. Am. J. Obstet. Gynecol. 161, 1200-1204
2. Department of Health (2000) CESDI Confidential Enquiries into Stillbirths and Deaths in Infancy, TSO, London
3. Department of Health (1998) Why Mother's Die. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 2000-2002, TSO, London
4. Neal, C. R., Hunter, A. J., Harper, S. J., Soothill, P. W. and Bates, D. O. (2004) Plasma from women with severe pre-eclampsia increases microvascular permeability in an animal model in vivo. Clin. Sci. 107, 399-405
5. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S. and Dvorak, H. F. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985
6. Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611
7. Sgambati, E., Marini, M., Zappoh Thyrion, G. D. et al. (2004) VEGF expression in the placenta from pregnancies complicated by hypertensive disorders. Br. J. Obstet. Gynaecol. 111, 564-570
8. Chung, J. Y., Song, Y., Wang, Y., Magness, R. R. and Zheng, J. (2004) Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J. Clin. Endocrinol. Metab. 89, 2484-2490
9. Ferrara, N. and Keyt, B. (1997) Vascular endothelial growth factor: basic biology and clinical implications. Experientia 79, 209-232
10. Wheeler, T., Elcock, C. L. and Anthony, F. W. (1995) Angiogenesis and the placental environment. Placenta 16, 289-296
11. Rajakumar, A., Whitelock, K. A., Weissfeld, L. A., Daftary, A. R., Markovic, N. and Conrad, K. P. (2001) Selective overexpression of the hypoxia-inducible transcription factor, HIF-2α, in placentas from women with preeclampsia. Biol. Reprod. 64, 499-506
12. Simmons, L. A., Hennessy, A., Gillin, A. G. and Jeremy, R. W. (2000) Uteroplacental blood flow and placental vascular endothelial growth factor in normotensive and pre-eclamptic pregnancy. Br. J. Obstet. Gynaecol. 107, 678-685
13. Baker, P. N., Krasnow, J., Roberts, J. M. and Yeo, K. T. (1995) Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet. Gynecol. 86, 815-821
14. Sharkey, A. M., Cooper, J. C., Balmforth, J. R. et al. (1996) Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and in pregnancies complicated by pre-eclampsia. Eur. J. Clin. Invest. 26, 1182-1185
15. McKeeman, G. C., Ardill, J. E., Caldwell, C. M., Hunter, A. J. and McClure, N. (2004) Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am. J. Obstet. Gynecol. 191, 1240-1246
16. Tranquilli, A. L., Bezzeccheri, V., Giannubilo, S. R., Scagnoli, C., Mazzanti, L. and Garzetti, G. G. (2004) Amniotic vascular endothelial growth factor (VEGF) and nitric oxide (NO) in women with subsequent preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 113, 17-20
17. Galazios, G., Papazoglou, D., Giagloglou, K., Vassaras, G., Koutlaki, N. and Maltezos, E. (2004) Umbilical cord serum vascular endothelial growth factor (VEGF) levels in normal pregnancies and in pregnancies complicated by preterm delivery or pre-eclampsia. Int. J. Gynaecol. Obstet. 85, 6-11
18. Roes, E. M., Steegers, E. A., Thomas, C. M. et al. (2004) High levels of urinary vascular endothelial growth factor in women with severe preeclampsia. Int. J. Biol. Markers 19, 72-75
19. Tsatsaris, V., Goffin, F., Munaut, C. et al. (2003) Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J. Clin. Endocrinol. Metab. 88, 5555-5563
20. Anthony, F. W., Evans, P. W., Wheeler, T. and Wood, P. J. (1997) Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins. Ann. Clin. Biochem. 34, 276-280
21. Hunter, A., Aitkenhead, M., Caldwell, C., McCracken, G., Wilson, D. and McClure, N. (2000) Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy. Hypertension 36, 965-969
22. Cooper, J. C., Sharkev, A. M., Charnock-Jones, D. S., Palmer, C. R. and Smith, S. K. (1996) VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br. J. Obstet. Gynaecol. 103, 1191-1196
23. Livingston, J. C., Chin, R., Haddad, B., McKinney, E. T., Ahokas, R. and Sibai, B. M. (2000) Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am. J. Obstet. Gynecol. 183, 1554-1557
24. Reuvekamp, A., Velsing-Aarts, F. V., Poulina, I. E., Capello, J. J. and Duits, A. J. (1999) Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br. J. Obstet. Gynaecol. 106, 1019-1022
25. Maynard, S. E., Min, J. Y., Merchan, J. et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658
26. Levine, R. J., Maynard, S. E., Qian, C. et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672-683
27. Koga, K., Osuga, Y., Yoshino, O. et al. (2003) Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J. Clin. Endocrinol. Metab. 88, 2348-2351
28. Brockelsby, J., Hayman, R., Ahmed, A., Warren, A., Johnson, I. and Baker, P. (1999) VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy, implications in the pathogenesis of preeclampsia. Lab. Invest. 79, 1101-1111
29. 165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123-4131
30. 165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64, 7822-7835
31. Bosio, P. M., Wheeler, T., Anthony, F., Conroy, R., O'Herlihy, C. and McKenna, P. (2001) Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am. J. Obstet. Gynecol. 184, 146-152
32. El-Salahy, E. M., Ahmed, M. I., El-Gharieb, A. and Tawfik, H. (2001) New scope in angiogenesis: role of vascular endothelial growth factor (VEGF), NO, lipid peroxidation, and vitamin E in the pathophysiology of pre-eclampsia among Egyptian females. Clin. Biochem. 34, 323-329
33. Kupferminc, M. J., Daniel, Y., Englender, T. et al. (1997) Vascular endothelial growth factor is increased in patients with preeclampsia. Am. J. Reprod. Immunol. 38, 302-306
34. Lyall, F., Greer, I. A., Boswell, F. and Fleming, R. (1997) Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br. J. Obstet. Gynaecol. 104, 223-228
35. Polliotti, B. M., Fry, A. G., Saller, D. N., Mooney, R. A., Cox, C. and Miller, R. K. (2003) Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet. Gynecol. 101, 1266-1274
36. Schlembach, D. and Beinder, E. (2003) Angiogenic factors in preeclampsia. J. Soc. Gyn. Invest. 10, 316A
37. Ahmad, S. and Ahmed, A. (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95, 884-891
38. Eremina, V., Sood, M., Haigh, J. et al. (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707-716
39. Perrin, R. M., Konopatskaya, O., Qiu, Y., Harper, S. J., Bates, D. O. and Churchill, A. J. (2005) Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48, 2422-2427
40. Huez, I., Bornes, S., Bresson, D., Creancier, L. and Prats, H. (2001) New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol. Endocrinol. 15, 2197-2210
41. Levy, N. S., Goldberg, M. A. and Levy, A. P. (1997) Sequencing of the human vascular endothelial growth factor (VEGF) 3′ untranslated region (UTR): conservation of five hypoxia-inducible RNA-protein binding sites. Biochim. Biophys. Acta 1352, 167-173
42. Cui, T. G., Foster, R. R., Saleem, M. et al. (2004) Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. Am. J. Physiol. Renal Physiol. 286, F767-F773
43. Bates, D. O. and Harper, S. J. (2005) Therapeutic potential of inhibitory VEGF splice variants. Future Oncol. 1, 467-473
44. Clark, D. E., Smith, S. K., He, Y. et al. (1998) A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol. Reprod. 59, 1540-1548
45. Kendall, R. L. and Thomas, K. A. (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Nat. Acad. Sci. U.S.A. 90, 10705-10709
46. Levine, R. J., Thadhani, R., Qian, C. et al. (2005) Urinary placental growth factor and risk of preeclampsia. JAMA, J. Am. Med. Assoc. 293, 77-85
47. Emmer, P. M., Joosten, I., Schut, M. H., Zusterzeel, P. L., Hendriks, J. C. and Steegers, E. A. (2004) Shift in expression of HLA-G mRNA spliceforms in pregnancies complicated by preeclampsia. J. Soc. Gynecol. Invest. 11, 220-226
48. Challier, J., Galtier, M., Bintein, T., Cortez, A., Lepercq, J. and Hauguel-de Mouzon, S. (2003) Placental leptin receptor isoforms in normal and pathological pregnancies. Placenta 24, 92-99
49. Moses, E. K., Freed, K. A., Higgins, J. R. and Brennecke, S. P. (1999) Alternative forms of a novel aspartyl protease gene are differentially expressed in human gestational tissues. Mol. Hum. Reprod. 5, 983-989